Oral antipsychotic update: A brief review of new and investigational agents for the treatment of schizophrenia

CNS Spectrums

Volumn 17, Issue SUPPL.1, 2012, Pages 1-9

  Citrome, Leslie ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antipsychotic; Asenapine; Bitopertin; Brexpiprazole; Cariprazine; Iloperidone; Lurasidone; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; BITOPERTIN; BREXPIPRAZOLE; CARIPRAZINE; HALOPERIDOL; ILOPERIDONE; LITHIUM; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

AKATHISIA; ANXIETY; ARTICLE; CLINICAL PRACTICE; COGNITIVE DEFECT; CONSTIPATION; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPESTHESIA; INSOMNIA; LONG TERM CARE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE RIGIDITY; NAUSEA; NOSE OBSTRUCTION; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TABLET DISINTEGRATION; TACHYCARDIA; TREMOR; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; HUMANS; LONG-TERM CARE; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84871430864     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852912000727     Document Type: Article

References (54)

1. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009; 10(12): 1917-1928.
2. Ballaz SJ, Akil H, Watson SJ. The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior. Neuroscience. 2007; 149(1): 192-202.
3. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr. 2004; 9(Suppl. 11): 6-14.
4. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S4-S11.
5. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo-and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S20-S28.
6. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2009; 63(8): 1237-1248.
7. Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2010; 64(6): 707-718.
8. Citrome L, Meng X, Hochfeld M, Stahl SM. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo-and active-controlled trials. Hum Psychopharmacol. 2012; 27(1): 24-32.
9. Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res. 2011; 131(1-3): 75-81.
10. Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S29-S35.
11. Novartis. Fanapt (iloperidone) tablets. Product label, revised January 2012. http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdf (accessed 19 July 2012).
12. AstraZeneca. Seroquel XR (quetiapine fumarate extended release). Product label, revised December 2011. http://www1.astrazeneca-us.com/pi/seroquelxr.pdf (accessed 19 July 2012).
13. AstraZeneca. Seroquel (quetiapine fumarate). Product label, revised December 2011. http://www1.astrazeneca-us.com/pi/seroquel.pdf (accessed 19 July 2012).
14. Marek GJ, Aghajanian GK. 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol. 1999; 367(2-3): 197-206.
15. th Edition, Cambridge University Press, Cambridge UK, February 2013 (in press).
16. Merck. Saphris (asenapine). Product label, revised May 2012. http://www.spfiles.com/pisaphrisv1.pdf (accessed 19 July 2012).
17. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010; 30(2): 106-115.
18. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial. J Clin Psychiatry. 2007; 68(10): 1492-1500.
19. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011; 72(3): 349-355.
20. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009; 63(12): 1762-1784.
21. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009; 11(7): 673-686.
22. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, doubleblind, placebo-controlled trial. J Affect Disord. 2010; 122(1-2): 27-38.
23. Szegedi A, Calabrese JR, Stet L, Mackle M, Zhao J, Panagides J, Apollo Study Group. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol. 2012; 32(1): 46-55.
24. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010; 43(4): 138-146.
25. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012; 32(1): 36-45.
26. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009; 11(8): 815-826.
27. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010; 126(3): 358-365.
28. Citrome L. Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat. 2011; 7: 325-339.
29. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(6): 829-836.
30. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study. Am J Psychiatry. 2011; 168(9): 957-967.
31. Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2012 Aug 19. [Epub ahead of print].
32. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011; 65(2): 189-210.
33. Sunovion. Latuda (lurasidone HCl). Product label, revised April 2012. http://latudahcp.com/LatudaPrescribingInformation.pdf (accessed 19 July 2012).
34. Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses. 2012; 6(2): 76-85.
35. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012; 27(3): 165-176.
36. th Annual Meeting, May 5-9, 2012, Philadelphia, Pennsylvania.
37. Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Therapy. 2012 Sep 20. [Epub ahead of print].
38. th Annual Meeting, May 5-9, 2012, Philadelphia, Pennsylvania.
39. th Annual Meeting, May 5-9, 2012, Philadelphia, Pennsylvania.
40. Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012; 13(11): 1599-1613.
41. Citrome L. Drug safety evaluation of ziprasidone. Expert Opin Drug Saf. 2011; 10(3): 437-448.
42. th Annual Meeting, June 14-17, 2010, Boca Raton, Florida.
43. th Annual Meeting, May 5-9, 2012, Philadelphia, Pennsylvania.
44. Knesevich MA, Papadakis K, Bose A, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar disorder: a phase II trial. Poster Presentation NR1-49, American Psychiatric Association 162nd Annual Meeting, May 16-21, 2009, San Francisco,. California.
45. th Annual Meeting, May 5-9, 2012, Philadelphia, Pennsylvania.
46. McQuade R, Hobart M, Forbes RA, et al. A Phase II trial assessing the efficacy and safety of OPC-34712 in the acute treatment of adult schizophrenia (Study 331-07-203). Poster Presentation 140, 2011 US Psychiatric Congress, November 7-10, 2011.
47. th Annual Meeting, May 14-18, 2011, Honolulu, Hawaii.
48. Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry. 2012; 25(2): 96-102.
49. th Annual Meeting, December 5-9, 2010, Miami Beach, Florida.
50. Kinon BJ, Gomez JC. Clinical development of pomaglumetad methionil: A non-dopaminergic treatment for schizophrenia. Neuropharmacology. 2012 Jun 18. [Epub ahead of print]
51. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007; 13(9): 1102-1107.
52. Kinon BJ, Zhang L, Millen BA, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011; 31(3): 349-355.
53. Eli Lilly. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study (press release). July 11, 2012. http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=690836 (accessed 19 July 2012).
54. Eli Lilly. Lilly Stops Phase III Development of Pomaglumetad Methionil for the Treatment of Schizophrenia Based on Efficacy Results (press release). August 29, 2012. http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=703018 (accessed 29 August 2012).